UCB SA (FRA:UNC)

Germany flag Germany · Delayed Price · Currency is EUR
250.00
+1.60 (0.64%)
Last updated: Oct 20, 2025, 8:04 AM CET
0.64%
Market Cap48.58B
Revenue (ttm)6.85B
Net Income (ttm)1.33B
Shares Outn/a
EPS (ttm)6.87
PE Ratio36.47
Forward PE28.46
Dividend0.97 (0.39%)
Ex-Dividend DateApr 25, 2025
Volumen/a
Average Volume64
Open250.00
Previous Close248.40
Day's Range250.00 - 250.00
52-Week Range135.90 - 260.90
Betan/a
RSI66.34
Earnings DateFeb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1925
Employees 9,378
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol UNC
Full Company Profile

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial Statements

News

There is no news available yet.